Variable | All patients n = 221 | Poor outcomea n = 94 | Good outcome n = 87 | p |
---|---|---|---|---|
Age | 37 (32–46) | 39 (33–47) | 36 (33–44) | 0.29 |
Male gender | 138 (62%) | 68 (72%) | 46 (53%) | 0.007 |
Unmarried | 106 (48%) | 45 (48%) | 45 (52%) | 0.61 |
Unemployed | 53 (24%) | 21 (22%) | 20 (23%) | 0.92 |
Living outside Yangon | 54 (24%) | 25 (27%) | 18 (21%) | 0.35 |
Did not complete high school | 153 (70%) | 64/92 (70%) | 62/87 (71%) | 0.80 |
Number of family members living at home | 3 (2–4) | 3 (2–4) | 4 (2–5) | 0.49 |
Per-capita household income (USD) | 48.07 (30.77–76.92) | 46.15 (30.77–76.92) | 51.28 (28.04–76.92) | 0.31 |
Hazardous alcohol consumption | 47/220 (21%) | 20/94 (21%) | 15/86 (17%) | 0.52 |
Current cigarette smoker | 56/211 (27%) | 27/89 (30%) | 16/82 (20%) | 0.12 |
Active injecting drug use | 3 (1%) | 1 (1%) | 2 (2%) | 0.61 |
Presently chewing betel nut | 77/200 (39%) | 37/84 (44%) | 26/77 (34%) | 0.18 |
Hepatitis B surface antigen positive | 21/206 (10%) | 7/89 (8%) | 7/77 (9%) | 0.79 |
Hepatitis C antibody positive | 6/206 (3%) | 2/89 (2%) | 2/77 (3%) | 1.0 |
Body mass index (kg/m2) | 19.1 (17.0–22.3) | 19.5 (16.6–22.6) | 19.5 (17.3–22.1) | 0.77 |
Mean arm circumference (cm) | 25 (22–27) | 25 (22–28) | 24 (22–27) | 0.70 |
WHO stage at enrolment | 1 (1–3) | 1 (1–3) | 1 (1–2) | 0.25 |
CD4 cell count (cells/mm3) | 92 (44–158) | 86 (41–145) | 99 (47–158) | 0.25 |
Receiving dolutegravir containing regimen | 181/219 (83%) | 78/93 (84%) | 76/87 (87%) | 0.51 |
Haemoglobin (g/dL) | 11.0 (9.6–12.8) | 10.4 (9.6–12.2) | 11.0 (9.7–12.9) | 0.33 |
Creatinine (µmol/L) | 88 (75–107) | 91 (77–111) | 91 (75–107) | 0.61 |